Noninvasive malignant thymoma

Summary

Noninvasive malignant thymoma (MONDO:0004147) is a disease. A subtype of thymoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	noninvasive malignant thymoma
Mondo ID	MONDO:0004147
DOID	DOID:7214
NCIT	C9080
UMLS	C0278847
MedGen	78893
GARD	0023848
Is cancer (heuristic)	no

Also known as: malignant thymoma, noninvasive · thymoma malignant noninvasive

Disease family

This is a subtype of thymoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › thymus neoplasm › thymic epithelial neoplasm › thymoma › noninvasive malignant thymoma

Related subtypes (7): encapsulated thymoma, thymoma type A, combined thymoma, invasive malignant thymoma, thymoma, familial, thymoma type B, thymoma type AB

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.